France’s HAS Denies Ribociclib Breast Can...

By Staff Writer

August 12, 2025

Ribociclib breast cancer therapy has been closely scrutinized as an adjuvant treatment for patients with early-stage HR-positive, HER2-negative breast cancer at high risk of recurrence. If you’re wondering, “Why did France’s HAS reject reimburseme...
FDA Approved Eye Drops: Lenz Therapeutics Launches VIZZ for Presbyopia Treatment
Donanemab Alzheimer’s Approval: A New Era in Treatment
AI in Real-World Evidence: Insights from Mitch Higashi
Navigating AI Act Implementation Challenges in MedTech
Thimerosal Vaccine Removal: HHS Finalizes Decision
Facilitators and Barriers in AI Medical Imaging Implementation: A Systematic ...
Model Type and Its Impact on Pneumococcal Vaccine Cost-Effectiveness in Germany
Revolutionizing Pathology: The GAS Intraoperative Diagnosis Platform
DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expan...
MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Onc...
NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patie...
Efficacy and Insights of Transdiagnostic Mental Health Apps for Depression an...